↓ Skip to main content

Caloric restriction versus drug therapy to delay the onset of aging diseases and extend life

Overview of attention for article published in GeroScience, May 2005
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
46 Mendeley
Title
Caloric restriction versus drug therapy to delay the onset of aging diseases and extend life
Published in
GeroScience, May 2005
DOI 10.1007/s11357-005-3284-4
Pubmed ID
Authors

Arthur V. Everitt, George S. Roth, David G. Le Couteur, Sarah N. Hilmer

Abstract

There are two firmly established methods of prolonging life. Calorie restriction (CR) using nutrient-rich diets to prolong life in lower animals, and life saving medications in humans to delay the development of the major diseases of middle and old age. These two approaches have different mechanisms of action. In rats, CR at 40% below ad libitum intake begun soon after weaning and continued until death, reduces body weight by about 40% and increases lifespan. There have been no lifelong CR studies performed on humans. However, in healthy adult human subjects about 20% CR over a period of 2-15 years, lowers body weight by about 20% and decreases body mass index (BMI) to about 19. This CR treatment in humans reduces blood pressure and blood cholesterol to a similar extent as the specific drugs used to delay the onset of vascular disease and so extend human life. These same drugs may act by mechanisms that overlap with some of the mechanisms of CR in retarding these pathologies and thus may have similar antiaging and life prolonging actions. Such drugs may be regarded as CR mimetics which inhibit the development of certain life shortening diseases, without the need to lower calorie intake. In developed countries, better medical care, drug therapy, vaccinations, and other public health measures have extended human life by about 30 years during the 20th century without recourse to CR, which is so effective in the rat. The percentage gain in human life expectancy during the 20th century is twice that achieved by CR in rat survival. However, rat longevity studies now use specific pathogen-free animals and start CR after weaning or later, thereby excluding deaths from infectious diseases and those associated with birth and early life. There is a need to develop CR mimetics which can delay the development of life-threatening diseases in humans. In the 21st century due to the human epidemic of overeating with a sedentary lifestyle, it may necessary to utilize CR to counter the aging effects of overweight. Since the greatest life-extending effects of CR in the rodent occur when started early in life, long-term antiaging therapy in humans should be initiated soon after maturity, when physiological systems have developed optimally.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
United States 1 2%
Italy 1 2%
Unknown 43 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 17%
Student > Postgraduate 7 15%
Other 5 11%
Student > Bachelor 5 11%
Student > Ph. D. Student 4 9%
Other 7 15%
Unknown 10 22%
Readers by discipline Count As %
Medicine and Dentistry 12 26%
Biochemistry, Genetics and Molecular Biology 6 13%
Agricultural and Biological Sciences 5 11%
Nursing and Health Professions 3 7%
Sports and Recreations 3 7%
Other 6 13%
Unknown 11 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2015.
All research outputs
#20,674,485
of 25,394,764 outputs
Outputs from GeroScience
#1,394
of 1,597 outputs
Outputs of similar age
#66,681
of 70,421 outputs
Outputs of similar age from GeroScience
#5
of 5 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,597 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.0. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 70,421 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.